The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
BioFluidica LiquidScan harnesses the power of microfluidics
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
Air purification system achieves Intertek zero ozone certification
Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Subscribe To Our Newsletter & Stay Updated
